The Valley of Death in anticancer drug development: a reassessment.

  • David J Adams
  • Published 2012 in Trends in pharmacological sciences

Abstract

The past decade has seen an explosion in our understanding of cancer biology and with it many new potential disease targets. Nonetheless, our ability to translate these advances into therapies is poor, with a failure rate approaching 90%. Much discussion has been devoted to this so-called 'Valley of Death' in anticancer drug development, but the problem… (More)
DOI: 10.1016/j.tips.2012.02.001

Topics

  • Presentations referencing similar topics